Combination Therapy for Inhibitor Reversal in Haemophilia A Using Monoclonal Anti-CD20 and Rapamycin

Development of antibodies (inhibitors) against coagulation factor VIII (FVIII) is a major complication of intravenous replacement therapy in haemophilia A (HA). Current immune tolerance induction (ITI) regimens are not universally effective. Rituximab, a B cell-depleting antibody against CD20, has s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thromb Haemost
Hauptverfasser: Biswas, Moanaro, Rogers, Geoffrey L., Sherman, Alexandra, Byrne, Barry J., Markusic, David M., Jiang, Haiyan, Herzog, Roland W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5222884/
https://ncbi.nlm.nih.gov/pubmed/27683758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1160/TH16-05-0404
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge